Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

| 药品名称 | 卡络磺钠注射液 | | --- | --- | | 剂型 | 注射剂 | | 规格 | 5ml：25mg（按C₁₀H₁₁N₄NaO₅S·3H₂O计）； | | | 10ml：50mg（按C₁₀H₁₁N₄NaO₅S·3H₂O计）； | | 注册分类 | 化学药品3类 | | 药品有效期 | 24个月 | | 上市许可持有人 | 四川汇宇海玥医药科技有限公司 | | 生产企业 | 山西振东泰盛制药有限公司 | | 受理号 | CYHS2300665；CYHS2300666； | | 证书编号 | 2025S01262；2025S01263； | | 药品批准文号 | 国药准字 H20254077；国药准字 H20254078； | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 | | | 药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说 | | | 明书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产 | | | 质量管理规范要求方可生产销售。 | 一、药品基本情况 二、药品的其他相关情况 卡络磺钠注射液能降低毛细血管的通透性，增进毛细血管断 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of its drug, Caroverine Sodium Injection, which is indicated for various bleeding disorders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has been granted a drug registration certificate for Caroverine Sodium Injection [1] - Caroverine Sodium Injection is designed to reduce capillary permeability, enhance the retraction of capillary rupture ends, and increase resistance to damage, thereby shortening bleeding time without affecting blood coagulation and fibrinolysis [1] Group 2: Market Potential - The drug is applicable for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology [1] - The projected sales revenue for Caroverine Sodium Injection in urban public hospitals in China for 2024 is estimated to be 3.39 million yuan [1] - The company has initiated preparatory work for the product's market launch and sales [1]

上 海 东 方 华 银 律 师 事 务 所 C A P I T A L L A W & P A R T N E RS 上海东方华银律师事务所 关于四川汇宇制药股份有限公司 2024 年年度股东大会 之 法律意见书 致：四川汇宇制药股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受四川汇宇制药股份有限 公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会的有关事宜， 根据《中华人民共和国公司法》（以下简称：《公司法》）、《上市公司股东会 规则》（以下简称：《股东会规则》）等法律、法规和其他规范性文件以及《四 川汇宇制药股份有限公司章程》（以下简称：《公司章程》）的有关规定，出具 本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东大会的相关资料， 包括但不限于公司召开 2024 年年度股东大会的通知、公司 2024 年年度股东大会 的议程、议案及决议等文件资料，同时听取了公司董事会秘书就有关事实的陈述 和说明。公司已向本所作出保证和承诺，保证公司向本所提供的资料和文件均真 实、准确、完整，无重大遗漏。 本所律师仅就本法律意见书出具日以前所发生的事实以及本所律师对有关 法律 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-038 四川汇宇制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 1、 公司在任董事8人，出席8人，现场结合通讯方式出席 8 人； 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 119 | | --- | --- | | 普通股股东人数 | 118 | | 特别表决权股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 509,746,632 | | 普通股股东所持有表决权数量 | 109,445,257 | | 特别表决权股东所持有表决权数量（每份特别表决权股份的 | 400,301,375 | | 表决权数量为：5） | | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 68.7266 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 14.7559 | （一） 股东大会召开的时间 ...

四川汇宇制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688553 证券简称：汇宇制药 公告编号：2025-037 四川汇宇制药股份有限公司（以下简称"公司"）于 2025 年 1 月 23 日召开 第二届董事会第十三次会议，审议通过了《关于聘任公司副总经理、董事会秘书 的议案》，经公司董事长提名，董事会提名委员会审核，董事会同意聘任张春平 先生为公司董事会秘书，由于张春平先生获聘时尚未取得上海证券交易所颁发的 科创板董事会秘书任职培训证明，暂由公司财务总监高岚先生代行董事会秘书职 责，对张春平先生董事会秘书职位的聘任于其取得相关证明后正式生效。具体内 容详见公司于 2025 年 1 月 25 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于公司董事、副总经理、董事会秘书辞职及聘任副总经理、董事会秘书的 公告》。 张春平先生近期已参加上海证券交易所科创板上市公司董事会秘书任职培 训并完成相关测试，取得董事会秘书任职培训证明。张春平先生的董事会秘书任 职资格已经在上海证券交易 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-037 四川汇宇制药股份有限公司 关于董事会秘书正式履职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）于 2025 年 1 月 23 日召开 第二届董事会第十三次会议，审议通过了《关于聘任公司副总经理、董事会秘书 的议案》，经公司董事长提名，董事会提名委员会审核，董事会同意聘任张春平 先生为公司董事会秘书，由于张春平先生获聘时尚未取得上海证券交易所颁发的 科创板董事会秘书任职培训证明，暂由公司财务总监高岚先生代行董事会秘书职 责，对张春平先生董事会秘书职位的聘任于其取得相关证明后正式生效。具体内 容详见公司于 2025 年 1 月 25 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于公司董事、副总经理、董事会秘书辞职及聘任副总经理、董事会秘书的 公告》。 联系电话：0832-8808000 电子邮箱：ir@huiyupharma.com 联系地址：四川省内江市市中区汉阳路 333 号 ...

汇宇制药2024年年报显示，上海爽飒为公司第六大股东。 中国经济网北京5月12日讯汇宇制药(688553.SH)近日发布公告称，因自身资金需求，股东上海爽飒企业 管理咨询事务所(有限合伙)(以下简称"上海爽飒")拟通过集中竞价或大宗交易的方式减持公司股份不超 过12,695,629股，合计减持股份比例不超过公司股份总数的2.997%。减持期间为自公告披露之日起15个 交易日后的3个月内。 截至公告披露之日，公司股东上海爽飒持有公司股份数量为12,695,629股，占公司总股本的2.997%；上 述股份来源于公司首次公开发行前取得的股份，且已于2022年10月26日起解除限售并上市流通。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资金 19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项目、补充 流动资金。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 2021年10月26日 ...

Group 1 - Baichuan Energy plans to reduce its shareholding by up to 26.82 million shares, accounting for 2% of the total share capital, due to personal investment and funding needs [1] - Jinhong Gas intends to distribute a cash dividend of 1.00 yuan per 10 shares, with the record date on May 15, 2025 [2] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1% of the total share capital due to liquidity needs [2][3] Group 2 - Jiadu Technology will cancel 10.20 million repurchased shares, reducing its total share capital from 2.143 billion shares to 2.133 billion shares [4] - ILE Home's shareholder plans to reduce its stake by up to 154,250 shares, accounting for 0.4778% of the total share capital, due to funding needs [5] - Lai Yifen has fully removed related batches of its honey date dumpling products from shelves due to consumer health concerns [6][7] Group 3 - CATL's vice chairman Li Ping and spouse plan to donate 4.05 million shares to Fudan University for establishing a research fund, reducing Li Ping's shareholding from 4.58% to 4.48% [8] - Shuanghuan Transmission's shareholders completed their reduction plan, selling a total of 6.69 million shares, accounting for 0.789% of the total share capital [9] - Chengfei Integration reported no significant changes in its business operations or external environment despite stock price fluctuations [10] Group 4 - Guizhou Tire's controlling shareholder plans to increase its stake by no less than 50 million yuan and no more than 100 million yuan within six months [11] - *ST Youshu's application to revoke the delisting risk warning has been approved, and its stock will resume trading under a new name [13] - Jingwei Huikai's shareholders plan to reduce their stake by up to 3% of the total share capital due to funding needs [14] Group 5 - Hualan Biological's major shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [15] - Huyou Pharmaceutical's shareholder plans to reduce its stake by up to 2.997% of the total share capital due to funding needs [16] - Dongpeng Holdings' shareholders plan to reduce their stake by up to 1.5% of the total share capital due to funding needs [17] Group 6 - Keleke's controlling shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [18] - Dongfang Ocean's major shareholder plans to reduce its stake by 1% of the total share capital due to investor redemption requests [19] - Yisheng Shares reported a sales revenue of 141 million yuan from white feather chicken seedlings in April, with a year-on-year decrease of 7.28% [20] Group 7 - Qujiang Cultural Tourism's controlling shareholder's 12 million shares are set to be auctioned due to contractual disputes, representing 4.70% of the total share capital [21] - Duople's shareholder plans to reduce its stake by up to 123,800 shares, accounting for 2% of the total share capital, due to personal funding needs [22][23]

Mergers and Acquisitions - *ST Jinke and its wholly-owned subsidiary's restructuring plan has been approved by the court [1] Performance Disclosure - Yisheng Shares reported a 7.28% year-on-year decline in sales revenue for white feather broiler chicks in April, with sales quantity at 48.932 million and revenue at 141 million yuan [2] Share Buyback and Increase - Guizhou Tire's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan [3] - Jiadu Technology will complete the cancellation of 10.2049 million repurchased shares on May 12, 2025, changing the purpose of these shares from employee stock ownership plan to capital reduction [4] Risk Matters - Hualan Shares announced that shareholder Ruizhong Life Insurance plans to reduce its stake by up to 3%, amounting to a maximum of 3.789267 million shares [5] - Dongpeng Holdings' shareholders plan to collectively reduce their stake by up to 1.5% of the company's total share capital [6] - Huilong Pharmaceutical's shareholder Shanghai Shuangsa plans to reduce its stake by up to 2.997%, equating to a maximum of 12.6956 million shares [7] Regulatory Actions - Pilin Bio received an administrative regulatory decision from the Shanxi Securities Regulatory Bureau, which includes corrective measures [8]